Method of immune insufficiency correction in patients with mechanical jaundice of non-tumour genesis

FIELD: medicine.

SUBSTANCE: invention relates to medicine, can be applied in resuscitation science, surgery, clinical immunology. For correction of immune insufficiency in patients with mechanical jaundice of non-tumour genesis in addition to complex traditional therapy of post-operational period from the first day after operation one time per day intravenously introduced is 1 ml of 1%-solution of glutoxim on autoblood, with its preliminary 30 minute incubation with 20 ml of autoblood. Treatment course is 5 sessions.

EFFECT: method makes it possible to increase treatment efficiency, reduce lethality, reduce duration of patient's presence in hospital.

2 tbl, 1 ex


The invention relates to medicine, can be used in surgery, intensive care, clinical immunology.

Intoxication, growing in acute inflammatory diseases biliary tract, disrupts the functioning of the immune system. This is manifested in the decrease in the number of circulating cellular elements, inhibition of growth, maturation and migration, accumulation of excessive amounts of circulating complexes of the antibody-antigen in the serum due to violations of the processes of elimination [1, 4].

The need to improve the results of surgical treatment of complicated forms of gallstone disease requires studying the features of violations of local and systemic immunity and ways of their correction, as well as the development of methods of prevention of postoperative complications [2, 8].

Given that all surgical patients with mechanical jaundice in some degree impaired functioning of the immune system, they are shown holding immunocorrective therapy from the first day of the disease [3, 7]. However, the high economic costs necessary for the acquisition of immunomodulators, do not allow all patients to carry out adequate immunotherapy.

Currently known methods targeted transport of drugs, which allow, along with the creation in C is not, covered pathological process, to create a high concentration of an administered drug, to minimize unwanted reactions to medication, can reduce therapeutic dose and the administration frequency. These methods can be based on the use of different media, with trapnest to specific organs or cells. In addition, this goal can be achieved by applying microcontainer, which can be liposomes, capsules of human albumin magnetic microspheres, microcapsules made of nylon and autoclutch blood [5].

Methods based on the use of cells autologous blood for the purpose of modifying their properties for directed transport under the General title of extracorporeal pharmacotherapy. From the point of view of biocompatibility in vitro pharmacotherapy is the most beneficial for targeted transport of drugs. Cells used for directional transport, called "universities etc" [7].

Now for immune in various diseases use Glutoxim[6, 8, 9, 10]. This preparation allowed 10.09.98 Pharmacological Committee of Russia for clinical use as a medicinal product, which is the modifier biological engineering is th answer with immunomodulatory properties (registration number 98/279/3).

According VFS (42-3195-98, 42-3408-99) drug Glutoxim is a chemically synthesized biologically active compound is a Hexapeptide with stabilized by a disulfide bond bis-(gamma-L-glutamyl)-L-cystinyl-bis-glycine disodium salt, with a total formula C20H20N6Na2O12S2[9]. Drug Glutoxim is a structural analogue of the natural metabolite of oxidized glutathione. Under the influence of Glutoxim is the proliferation and differentiation of normal cells of the immune system and activates the apoptosis of transformed cells. Artificial stabilizing disulfide bond of oxidized glutathione allows enhancement of multiple physiological effects, natural remotefilename oxidized glutathione. Glutoxim activates antivarikoznye the enzyme glutathion reductase, glutationtransferase and glutathione peroxidase, which in turn activate intracellular reactions of thiol metabolism and is necessary for normal functioning of the intracellular regulatory systems. The cells in the new redox mode determines immunomodulatory and cytoprotective system effect of the drug. Based on the mechanisms of action of this drug can distinguish the following main functions: a ) endogenous products, modification and reproduction effects of cytokines; 2) selective effect on normal and transformed cells. Glutoxim it is recommended to enter systemically (intravenously, intramuscularly, subcutaneously) and regional (intrapleural, intrahepatic, intraperitoneally) [9, 10].

The disadvantage of these techniques is that for effective metabolic and immunocorrective action Glutoxim insufficient permeability of the membrane of lymphocytes. Bioavailability of Glutoxim is 80%, with an increase in membrane permeability of the lymphocyte to Glutoxim may enhance the bioavailability and thus increase immunocorrective effect of this drug.

The objective of the invention is the increased efficiency results after surgical treatment and immunotherapy in patients with mechanical jaundice nonneoplastic Genesis, reducing mortality, reducing the length of stay of patients in hospital.

The task to solve due to the fact that additional intravenously injected Glutoxim 1%1 ml pre-incubated with 20 ml of whole autologous blood, once daily therapy 5 sessions.

The method is as follows. From the first day of the postoperative period carry out intravenous infusion of antibiotics, colloid and crystalloid solutions, solutions,correcting acid-base status and electrolyte balance, and additionally injected Glutoxim 1%1 ml pre-incubated with 20 ml of whole autologous blood within 30 minutes, once a day, the course of therapy 5 sessions.

For evaluation of immune status of patients was determined indicators leukogram, indicators of cellular, humoral immunity.

To determine leukogram patients in the morning on an empty stomach collect blood from a finger. The absolute number of leukocytes is determined in the Goryayev camera according to the standard technique. The morphology of leukocytes and the percentage of each population estimate after staining the smear of blood surasena. Next, calculate the absolute number of lymphocytes.

Simultaneously with blood sampling from the finger conduct blood from the cubital vein for isolation of lymphocytes, which are further used to phenotype by monoclonal antibodies and determination of structural and metabolic parameters (enzyme activities and lipid profile). The preservative is 0.6 percent cooled to 4-5°C buffer solution at physiological solution, which is mixed with blood in a ratio of 1:9. Allocate a suspension of lymphocytes from the blood. For the subsequent determination of enzymes activity of lymphocytes separated 1 million cells and freeze them at -20°C, to study lipid spectrum freeze 2 million cells.

Phenotypicaly the th lymphocytes carried out by indirect immunofluorescence using mouse monoclonal antibodies to molecules of different CD-receptors of lymphocytes. Sample analysis is performed on a fluorescent microscope Lumam And-1. In the use of murine monoclonal antibodies JSC "Sorbent" to CD3 (T-lymphocytes), CD4 (T-helper cells), CD8 (T-suppressor), CD 19 (b-lymphocytes).

The number of b-lymphocytes is determined by the expression of receptors type 19 in the reaction of indirect immunofluorescence. The functional activity of b-lymphocyte count at the level of the main classes of immunoglobulins in the serum IgA, IgG, IgM. The concentration of serum immunoglobulins A, M, G determined by the method of radial immunodiffusion using diagnostic monospecific human sera. This method is based on measuring ring precipitation formed when making the test serum in wells cut in the layer of agar, which is pre-dispersed monospecific serum. In standard conditions experience the diameter of the ring precipitation is directly proportional to the concentration of the studied immunoglobulin. The immunoglobulin set relative to a reference human serum with a known concentration of immunoglobulins.

The study included 43 patients with mechanical jaundice of non-neoplastic origin. Were diagnosed on the basis of complaints, anamnesis, clinical and laboratory data, results of examination and ultrasound hepato-pancre then-duodenal area, and on the testimony was performed endoscopic retrograde cholangiopancreatography (ERCP). Surgery was performed in all patients at different times after admission to the hospital. The scope of the operation was to laparotomy, choledocholithotomy, establishing drainage of the choledochus.

All patients from the first day the early postoperative period conducted intensive therapy, including antibiotics and infusion therapy, detoxification treatment in the intensive care unit and intensive care.

The patients were divided into 3 groups. The first group consisted of patients who received postoperative traditional intensive therapy. In the second group, along with traditional treatment, patients received Glutoxim 1%1 ml, administered intravenously. Patients of the third group in addition to treatment was administered intravenous Glutoxim 1%1 ml pre-incubated with 20 ml of whole autologous blood within 30 minutes, once a day, therapy - 5 sessions.

All patients in the dynamics of clinical, biochemical and immunological blood tests.

The data obtained immune status were analyzed according to the main rules of interpretation immunograms. When processing the results of a study in patients with mechanical jaundice nonneoplastic Genesis revealed a number of features that differentiate them from regional indicators of leukogram and immunograms healthy person.

The results are presented in table 1, show that in patients receiving conventional therapy (group 1), on the 5th day after the treatment remains leukocytosis, lymphopenia, monocytosis. Patients of the second group receiving Glutoxim intravenously, was marked lymphocytosis and monocytosis, but unlike the patients of the first group, the total number of leukocytes was close to normal. In the patients on the background of traditional therapy in vitro drug therapy (group 3), indicators leukogram strive to normal.

When using the proposed method, the faster the relief of acute inflammatory reactions and reduced toxicity. Along with this and figure lymphocytes reaches the norm and becomes 2 times higher than in the group of patients receiving conventional therapy, which also confirms expressed detoxifying effect of our proposed method (table 1).

The results of immunological indexes presented in table 2, show that patients of the first group who received traditional therapy, on the 5th day after the treatment was preserved lymphopenia, T-immunodeficiency mild decline immunoregulatory index, due to the reduction of T-helper cells and the increase in T-suppressor cells, humoral link of an increased rate of immunoglobulin A.

Patients of the second group, polucha is their Glutoxim subcutaneously, in comparison with the indicators of the first group, continued T-immunodeficiency mild, but the level of lymphocytes and immunoregulatory index increased by increasing the level of T-helper cells and reduced T-suppressors.

In patients of the third group treated against the background of traditional therapy extracorporeal pharmacotherapy is a minor T-immunodeficiency, although the numbers of T-helper cells increased, respectively, the T-suppressor decreased, immunoregulatory index is close to the norm, humoral also is within normal limits.

By the 5th day of therapy in patients of the third group was achieved normalization of clinical and laboratory parameters that were not detected in patients first and second groups.

Mortality in the first group was 28%in the second group, 24% and in the third group of 10%. The duration of hospital stay decreased from 28.2 in the first group, to 17.4 in the second group, to 8.4 bed-day in the third group of patients.

Causes of death in the first and second groups was the development of pronounced syndrome of endogenous intoxication, multiple organ failure or purulent septicemic complications. In the third group cause of death (one patient) were advanced age (82 years) of the patient, which revealed severe concomitant pathology./p>

The effectiveness of the proposed method is proved by clinical observations of patients with mechanical jaundice of non-neoplastic origin. The proposed method can effectively influence the immune system by creating in immunocompetent cells high concentrations of metabolic immunocorrector - Glutoxim. As a result of exposure on metabolic and energetic processes in the immunocompetent cells decreased the degree of immunodeficiency in mechanical jaundice nonneoplastic origin and correspondingly increased the effectiveness of treatment, decreased mortality, decreased duration of hospital stay.


Patient T., born in 1961, was admitted in surgical ward Road clinical hospital at the station Krasnoyarsk 15.10.2008, with complaints about the yellowness of the skin and sclera, pressing pain and feeling of heaviness in the right hypochondrium, weakness. From the anamnesis: ill 3 days ago, when after errors in diet (fried pork meat, alcoholic drinks) appeared moderate pain and feeling of heaviness in the right hypochondrium. After one day the patient noticed the yellowing of sclera and skin, with pain intensified; analgesics (aspirin, baralgin) and antispasmodics (drotaverine, papaverine) is without effect. Caused the brigade emergency medical the first means, delivered in Road clinical hospital of Krasnoyarsk.

On physical examination, the patient's condition is moderate, there is a yellowness of the skin and sclera. The rhythmic heart sounds, pulse 86 beats per 1 minute, satisfactory filling. HELL 140/95 mm Hg vesicular Breath, wheezing is not heard. Belly symmetrical, moderately tense, painful in the right hypochondrium. In the clinical analysis of blood: erythrocyte sedimentation rate (ESR) 35 mm/h, WBC 17,8*109/l; stab 10%; segmented 50%; lymphocytes 16%; monocytes 9%; eosinophils 6%. Blood biochemical parameters: bilirubin 84,72 µmol/l, alanine aminotransferase 78,84 U/l, aspartate aminotransferase 57,33 U/l, alkaline phosphatase 254,36 U/l, gammaglutamyltranspeptidase 397,53 U/L. Immunological indicators: reduction of T-helper cells to 22,55%; a sharp decline in T-suppressor to 11,53%, increasing ratio of CD4/CD8 (immunoregulatory index) - 1,95. Ultrasound of the abdomen: hepatomegaly. Diffuse changes in the pancreas and liver. Dilatation of the common bile duct to 1.3 cm in the distal of which there is a calculus to 1.0 cm in diameter. The thickened wall of the gallbladder to 0.9 cm in the lumen are multiple concretions from 0.3 to 1.1 cm in diameter.

Clinical diagnosis: cholelithiasis. Choledocholithiasis. Mechanical is Kai jaundice.

In an emergency procedure performed ERCP and endoscopic papillosphincterotomy, lithoextraction. In the postoperative period the patient on the background of integrated traditional antispasmodic, antibacterial and detoxifying therapy in addition to treatment was administered intravenous Glutoxim 1%1 ml pre-incubated with 20 ml of whole autologous blood within 30 minutes, once a day, the course of therapy 5 sessions. The postoperative course was satisfactory, there were no complications, jaundice cropped, indicators of bilirubin, liver enzymes and immunological blood counts are normal. The patient was discharged on the 8th day in a satisfactory condition.

Sources of information

1. Wagner, E.A., V.V. Khlebnikov, Terekhina N.A. and other Antioxidants in the treatment of patients with cholelithiasis // News, surgery, 1997, No. 5, p.36-39.

2. Hulman M.I., Vinnik US, Cherdantsev A.I. and other Surgical tactics in various forms calculous cholecystitis in patients with high surgical risk // Sovr. chirurgic. Technology, Krasnoyarsk, 2006, p.50-57.

3. The Danovich SUPERVISION, Levers G.P., Nazarenko, M. the Role of ERCP in the diagnostic algorithm of pancreatobiliary disease // Ann. chirurgic. Hepatology, 2004, Vol.3, No. 3, p.55-56.

4. Nazarov I.P., Vinnik US, Sagar PV and other Immunity in surgery. Volume 2. - Krasnoyarsk, 2006. - 336 S.

5. To salacova N.I. Immunotherapy in treatment of purulent surgical infection: author. dis. Kida. the honey. Sciences. - Krasnoyarsk, 1990. - 21 S.

6. Borisov A.M. Clinical application of national drug polyoxidonium in secondary immunodeficiencies adults / Amerisave, Lventions, Nchsicdciwho // Therapist, architect. - 1998 - No. 10. - P.52-57.

7. Yoshino M., Murakami, K. Role of glutamate dehidrogenase reaction in the control of citrate pool in yeast // Int.J.Biochem. - 1993. - Vol.25, No. 12. - P.1723-1729.

8. RF patent №2190422, A61K 38/08, BIPM No. 28, 10.10.2002,

9. RF patent №2311174, A61K 31/11, BIPM No. 33, 27.11.2007,

10. RF patent №2197984, A61K 38/08, BIPM No. 4, 10.02.2003,

Treatment of immune deficiency in patients with mechanical jaundice nonneoplastic origin, characterized in that perform the surgery, then from the first day have integrated traditional therapy postoperative period and once daily intravenously injected 1 ml of 1%solution Glutoxim on autologous blood, with its pre-incubated for 30 min with 20 ml of autologous blood, the treatment course of 5 sessions.


Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to clinical immunology and aims at patient-specific immunotherapy. That is ensured by the use in a nidus zone of supernatant of stimulated autologous leukocytes with the concentration of neutrophilic antimicrobial peptides in supernatant not less than 2000 pg/ml. Supernatant is administered in applications and/or subcutaneously, or submucosally, or in instillations for 5-10 days.

EFFECT: method provides prevention of secondary immunodeficiency, reduced inflammation, wound decontamination, stimulated repair, allows lower dosages and period of administering antibiotics, due to joint action of a complex of cytokines and antimicrobial neutrophilic peptides produced by autologous leukocytes.

6 cl, 3 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is application of immobilised oligonucleotides as immunostimulating and hemostimulating medication for peroral introduction. Immobilised on polyethylene oxide oligonucleotides of DNA of salmon soft roes demonstrate immuno- and hemostimulating activity in conditions in vivo in case of peroral introduction in experimental animals and in vitro, which is manifested in stimulation of phagocytic reactions in vivo and in vitro, increase of IFN-γ in vitro, increase of cytotoxic activity of natural killers, increase of spontaneous proliferative activity of lymphoid cells of experimental animals and index of B-lymphocyte stimulation, increase of nitrogen oxide production, as well as in enchancement of hemopoiesis regeneration in early terms after cytostatic impact.

EFFECT: immobilised by physical method oligonucleotides are protected from destruction in gastrointestinal tract, which facilitates their permeability through intestine wall and increases bioavailability.

11 tbl

FIELD: medicine, veterinary science.

SUBSTANCE: method for preparing an immunostimulating drug for animals consists in the fact that stevioside is dissolved in 0.9 % physiologic saline, the prepared solution is added to pre-grinded lecithin, then olive oil heated to 35-40°C is introduced gradually in the prepared composition and mixed; further the prepared solution is filtered and autoclaved at temperature 115-120°C for 15-20 minutes, then the produced sterile drug is bottled and corked up. The immunostimulating drug for animals contains stevioside, 0.9 % physiologic saline, olive oil, lecithin in a certain ratio.

EFFECT: higher viability and productivity of animals by correcting body immune responsiveness.

2 cl, 4 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely to creation of medication, stimulating immunostimulating action, which represents liquid extract of burdock greater and woolly burdock roots, taken in ratio 1:1, obtained by method of repercolation with 40% ethanol.

EFFECT: medication extends arsenal of immunostimulating medications, amplifies humoral immune response, phagocytic activity of peripheral blood neutrophilsand peritoneal macrophages.

3 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely to creation of medication, stimulating immunostimulating action, which represents liquid extract of marsh-mallow roots, obtained by method of repercolation with 40% ethanol.

EFFECT: medication extends arsenal of immunostimulating medications, amplifies humoral immune response, cell immune response and phagocytic activity of peripheral blood neutrophils.

3 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to the development of new drugs for inflammatory diseases, particularly asthma. The pharmaceutical compositions under the invention contain 1-methyl-2-phenylthiomethyl-3-carbethoxy-4-dimethylaminomethyl-5-oxy-6-bromoindole in the effective amount or its pharmaceutically acceptable salts and/or hydrates as an active ingredient. The drug can be presented in the form of tablets, capsules, injections or aerosol.

EFFECT: provided anti-inflammatory and antiasthmatic action, as well as practically absolute absence of by-effects proper for the formerly known drugs administered for the same intended purpose.

10 cl, 4 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: there are offered specific antibodies linked at least with KIR2DL1, KIR2DL2, KIR2DL3 human receptor, neutralise KIR-mediated NK cytolergy inhibition in relation to Cw3+ or Cw4+ target-cells. There are described: B-lymphocyte hybrid cell for producing the antibodies, versions of the method for producing the antibody, as well as a method for detecting a NK-cell, a method for purifying the NK-cells with the use of the antibody and versions of the pharmaceutical antibody composition. Using the antibody for preparing a medicinal agent is offered.

EFFECT: use of the invention provides producing the antibody which controls NK cytolergy of various types, intensifies cytotoxicity, increases NK cytolergy or cytotoxicity in individuals.

63 cl, 13 dwg, 3 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to method for production of complex immunotropic preparation for animals, including mixing 90 wt parts of 0.2-0.3 % agar suspension, 2.5 wt parts of concentrate of purified polysaccharide complex, 3.5 wt parts (-)2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]-thiazole hydrochoride, 0.2 wt parts of formalin and 7.0 wt parts of antibiotic ceftriaxone.

EFFECT: increased non-specific resistance and immunogenesis, prophylactics and treatment of inflammatory processes in animals.

3 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely to creation of immunostimulating medication. As said medication, applied is liquid extract of three-lobe beggarticks, obtained by method of repercolation by means of 40% ethanol in ratio 1:1.

EFFECT: medication enhances humoral immune response, promotes growth of level of peripheral blood neutrophils phagocytosis, correction of immunodeficiency state, caused by introduction of cytostatic drug.

4 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary and cattle breeding. Method includes intramuscular or subcutaneous introduction of biogenic stimulator. Stimulator contains (g): 30.0 g of tissue emulsion from bodies of zoophilic fly larvae, 59.8 g of 0.9% solution of table salt in terms of sodium chloride, 10.0 g of natural May bee honey and 0.2 g of formalin. The said medication is introduced to an ill animal in dose 0.02-0.05 ml/kg of weight.

EFFECT: method efficiently activates functioning of protective systems of organism.

1 ex

FIELD: medicine.

SUBSTANCE: blood product filtration through filter, filled with carrier, covered with polymer, is performed. Said polymer is formed by three elements: element derived from hydrophobic polymerised monomer, element, derived from polymerised monomer, which contains main nitrogen-containing part, and element, derived from polymerised monomer, which contains proton neutral hydrophilic part as balance. After filtration collection of blood product is carried out. Efficiency of pathologic prion protein removal constitutes from 1.2 to 4.1 and higher.

EFFECT: efficient removal of pathologic prion protein from blood product with simultaneous removal of leukocytes.

12 cl, 1 dwg, 1 tbl, 23 ex

FIELD: medicine.

SUBSTANCE: sampling of blood from patient's ulnar vein with first and second syringe-test-tubes is carried out. First syringe-test-tube is centrifuged with acceleration 250 g for 10 minutes. Formed plasma and coagulated blood in second syringe-test-tube are centrifuged with acceleration 1000 g for 10 minutes. Platelet-poor plasma is separated from platelet-enriched plasma. Activator of platelet-enriched plasma is prepared from supernatant fluid after centrifugation of coagulated blood and platelet-poor plasma, with weight ratio in fractions: 1:1, and 10% calcium chloride solution. The latter - in drop manner, mixing until required mixture concentration is obtained. Platelet-enriched plasma is mixed with activator with weight ratio in fractions 1:3 respectively.

EFFECT: application of method allows to realise more complete isolation of platelets from sampled blood, which increases efficiency, physiologicity and safety of obtained plasma.

2 cl

FIELD: medicine.

SUBSTANCE: system includes a kit of disposable elements for transportation of liquid, which are preliminarily connected or include aseptic connectors for creation of connections between them in aseptic way, or are adapted for being aseptically connected. Kit includes three sets of disposable sterile elements: set for collection, set for processing and set for transplantation, packed in blister packing on carrier, such as tray, which has one department, containing each connected with other set of said kit. System can be applied for obtaining platelet concentrate for separate application. Method of collection and processing of cell subpopulation includes collection of isolated cells in collection chamber, connected with isolation device, processing of cells in centrifugal operation chamber, which is the same chamber as the chamber for collection, or which is connected with collection chamber, and collection of processed cells in chamber for reinfusion, which also is the same chamber as the operation chamber, or which is connected with operation chamber, and delivery of processed cell subpopulations back to the patient.

EFFECT: application of invention makes it possible to ensure automatic processing in closed system in on-line mode.

17 cl, 9 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery, and can be used in treating patients with secondary lymphedema of upper extremities. That is ensured by the introduction of autolymphocytes extracorporally processed with Roncoleukin and dissolved in normal saline in subcutaneous fat of an injured extremity in a projection of lymph node basins along a medial and lateral surface of forearm. The solution is introduced in 20 points by 0.5 ml containing 20 to 30 million cells per each point on the average. The procedures are thrice-repeated every 72 hours.

EFFECT: method allows to intensify lymphatic outflow from the injured extremity, to reduce paravasal inflammations of subcutaneous fat due to stimulating cell components of the immune system.

8 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves the intravenous and/or intramuscular introduction of the drugs used in myelopathy, balneotherapy in the form of baths. Acupressure and manual therapy are applied in addition. The manual therapy requires such techniques, as ischemic compression, release phenomenon, fascial broach, postisometric relaxation of the muscles involved in a pathological process. Discontinuous therapeutic plasmapheresis is applied with using either Baxter, or Bekman, or Haemophoenix apparatuses, and/or extracorporal ultraviolet blood irradiations is ensured by the apparatus Isolda MD 73 M. The apparatus Cryo-Jet is used for cryotherapy with cooled dry air at the level of degenerative dystrophic changed vertebral motor cervical segments and muscle attachment points.

EFFECT: method improves clinical effectiveness due to fast pain management, enlarged range of active and passive motions, normalised muscular tonus, increased muscular strength and corrected vegetovascular disorders.

6 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, oncology, and can be used for treatment of malignant lung neoplasms in experiment. For this purpose performed is extracorporal irradiation of autoblood with red incoherent light λ=0.67 mcm dose W=3.06 J/cm2 in continuous mode with exposition duration to three minutes. After that 15-20 minutes later into said blood added is cyclophosphane in dose 40 mg/kg and the mixture is incubated for 40 minutes at T=37°C. After that it is re-infused into subclavian vein of the animal.

EFFECT: claimed method allows to reduce terms of anti-tumour treatment, increase efficiency of cyclophosphane action, reduce its toxic manifestations, increase animals' life term, increase non-specific anti-tumour resistance, activate anti stressor mechanisms.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gynecology and concerns the integrated treatment of tuboperitoneal infertility. That is ensured by low-intensity infrared lasing at power 150 Wt, wave length 0.89 mcm of the inguinal lymph nodes and a skin projection of the lumbosacral plexus. The exposure time is 1 min for each region for 1st session. Thereafter, the exposure time is increased to 3 minutes during 10 sessions. It is combined with local intraendometrial introduction of an antibacterial agent and an immunomodulator. Besides the treatment involves a number of plasmapheresis sessions and introduction of nonsteroidal anti-inflammatory drugs, antioxidants, desensitisers, and vaginal sanitation.

EFFECT: method provides effective restoration of menstruation and reproductive function.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery and intensive therapy, and can be used in treating endotoxicoses caused by septic conditions. That is ensured by removal of a destruction area to be thereafter sanitised and drained. It is followed with lymphostimulating therapy by introduction of 0.25% Novocaine 60 ml with dissolved 0.1 g of Lydase and 1.0 ml of Pentoxifylline into the interspinous spaces in number of 1-3 injections. Further, discrete plasmapheresis in amount 400 ml for severe patients and 800 ml in moderate patients is applied in number of 1-8 procedures. The lymphostimulating therapy is alternated every second day with lymphotropic extracorporal pharmacoimmunotherapy with using a medicated mixture prepared by incubation of 40-60 ml of the patient's plasma with received plasma of the patient with Roncoleukin in dosage 500-1 million UN and Cefabol in dosage 1 g for 45 min at 37°C. In peritonitis and peritoneal sepsis, the medicated mixture is introduced in the bolus form in the retroperitoneal fat. The destructive processes in the pleural cavity require introduction of said mixture in the axillary cavity.

EFFECT: method provides endotoxin weakening in the bloodstream, intertissue spaces and cavities due to combined multidirectional local and system effect on the lymphoid system.

3 cl, 8 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dermatology, and can be used for treating patients with psoriasis. Method includes drug therapy with application of hyposensibilising anti-histamine medications, hepatoprotectors, vitamins, local exfoliating and releasing ointments, general ultraviolet oirradiation. Method also includes plasmapheresis with division of blood into plasma and erythrocyte mass by centrifugation with removal of patient's plasma and erythrocyte mass reinfusion. Before returning erythrocyte mass into patient's organism it is processed with 200 ml of ozonised physiological solution with ozone concentration 2.5 mg/l. After that reinfusion of ozonised erythrocyte mass is carried out.

EFFECT: method allows to increase efficiency of psoriasis treatment due to reduction of PASI index level, correction of disturbed indices of hemostasis and lipid exchange.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in contraction of anaemia accompanying the chemoradiation therapy. That is ensured by blood exfusion in amount 8-10% of the circulating blood volume, and the removed blood volume is replaced with crystalloids in the ratio 1:1. From the exfused blood, erythrocyte concentrate is recovered whereto Essentsiale N solution 5 ml is added; the prepared mixture is placed in a thermostat at temperature 37°C for 10 minutes. Then 100 ml of a physiologic saline is added to said mixture that is rocked. The prepared solution is introduced to the patient within 20 minutes with a simultaneous UV blood irradiation. Exfusion and extracorporal blood processing combined with UV irradiation are performed every second day, 2-3 sessions for the therapeutic course.

EFFECT: method allows reducing time for normalisation of the blood erythrocyte level and haemoglobin with maintaining the time intervals for chemoradiation therapy courses and without reducing the dosage of chemopreparations and radiation tumour load.

2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to method for production of complex immunotropic preparation for animals, including mixing 90 wt parts of 0.2-0.3 % agar suspension, 2.5 wt parts of concentrate of purified polysaccharide complex, 3.5 wt parts (-)2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]-thiazole hydrochoride, 0.2 wt parts of formalin and 7.0 wt parts of antibiotic ceftriaxone.

EFFECT: increased non-specific resistance and immunogenesis, prophylactics and treatment of inflammatory processes in animals.

3 tbl, 5 ex